HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account

Clinical Trial


Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

          This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.

Est. Enrollment: 80 participants

The number of participants in a clinical study. The "estimated" enrollment is the target number of participants the researchers need for the study.

Study Start Date: Jun 02, 2017

These are the dates the researchers think the study will start and end.

Study Completion Date: Jun 30, 2024

The "estimated" study completion date is the date the researchers think the last participant in a clinical study was examined or received an intervention/treatment. This is also the expected date that the study will be completed

Age: 18+ years

Gender: Female

Who can join expand_less
  • At least 18 years of age
  • International Myeloma Working Group (IMWG) criteria for the diagnosis of either MGUS or MM
Who cannot join expand_less
  • Unable to provide consent
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3
  • Hemoglobin < 8 g/dL
  • Women who are pregnant
  • Prior history of adverse events with conscious sedation
Study Description expand_more
Study Details expand_more

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology

Follow Us

facebook instagram twitter youtube